Long term outcomes with emicizumab in hemophilia A without inhibitors result from HAVEN 3 and 4 studies

dc.article.end-page12en
dc.article.start-page1en
dc.citation.doi10.1016/J.RPTH.2024.102364en
dc.contributor.authorJohnny Mahlanguen
dc.contributor.authorVíctor Jimenez-Yusteen
dc.contributor.authorGiuliana Ventrigliaen
dc.contributor.authorMarkus Nigglien
dc.contributor.authorSimona Barleraen
dc.contributor.authorE et alen
dc.date.accessioned2024-10-18T20:48:33Z
dc.date.available2024-10-18T20:48:33Z
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2475-0379en
dc.identifier.urihttps://hdl.handle.net/10539/41703
dc.journal.titleLong term outcomes with emicizumab in hemophilia A without inhibitors result from HAVEN 3 and 4 studiesen
dc.journal.volume8en
dc.publisherWILEY-BLACKWELLen
dc.titleLong term outcomes with emicizumab in hemophilia A without inhibitors result from HAVEN 3 and 4 studiesen
dc.typeJournal Articleen
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Journal Article.pdf
Size:
2 MB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client